Interferon-β Produces Synergistic Combinatory Anti-Tumor Effects with Cisplatin or Pemetrexed on Mesothelioma Cells

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Li, Quanhai ^a,b   Kawamura, Kiyoko ^a   Yang, Shan ^a,b   Okamoto, Shinya ^c   Kobayashi, Hiroshi ^c   Tada, Yuji ^b   Sekine, Ikuo ^b   Takiguchi, Yuichi ^b   Shingyouji, Masato ^a   Tatsumi, Koichiro ^b   Shimada, Hideaki ^d   Hiroshima, Kenzo ^e   Tagawa, Masatoshi ^a,b  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CISPLATIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEMETREXED; PROTEIN P53; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; INTERFERON RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL FRACTIONATION; CELL POPULATION; CELL VIABILITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MESOTHELIOMA; P53 GENE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GENE; UPREGULATION; WILD TYPE; ANALOGS AND DERIVATIVES; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; GLUTAMATES; GUANINE; HUMANS; INTERFERON-BETA; MESOTHELIOMA; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84881595858     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072709     Document Type: Article

References (28)

1. Carbone M, Kratzke RA, Testa JR, (2002) The pathogenesis of mesothelioma. Semin Oncol 29: 2-17. doi:10.1053/sonc.2002.37355. PubMed: 11836664.
2. Robinson BW, Musk AW, Lake RA, (2005) Malignant mesothelioma. Lancet 366: 397-408. doi:10.1016/S0140-6736(05)67025-0. PubMed: 16054941.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644. doi:10.1200/JCO.2003.11.136. PubMed: 12860938.
4. Lee AY, Raz DJ, He B, Jablons DM, (2007) Update on the molecular biology of malignant mesothelioma. Cancer 109: 1454-1461. doi:10.1002/cncr.22552. PubMed: 17348013.
5. Li Q, Kawamura K, Yamanaka M, Okamoto S, Yang S, et al. (2012) Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Ther 19: 218-228. doi:10.1038/cgt.2011.86. PubMed: 22223137.
6. Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, et al. (2008) Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 226: 29-40. doi:10.1111/j.1600-065X.2008.00698.x. PubMed: 19161414.
7. Li M, Liu X, Zhou Y, Su SB, (2009) Interferon-λs: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 86: 23-32. doi:10.1189/jlb.1208761. PubMed: 19304895.
8. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA, (2012) Pharmacology and therapeutic potential of interferons. Pharmacol Ther 135: 44-53. doi:10.1016/j.pharmthera.2012.03.006. PubMed: 22484806.
9. Parra HS, Tixi L, Latteri F, Bretti S, Alloisio M, et al. (2001) Combined regimen of cisplatin, doxorubicin, and alpha-2β interferon in the treatment of advanced malignant pleural mesothelioma: a phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer 92: 650-656. doi:10.1002/1097-0142(20010801)92:3. PubMed: 11505411.
10. Halme M, Knuuttila A, Vehmas T, Tammilehto L, Mäntylä M, et al. (1999) High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 80: 1781-1785. doi:10.1038/sj.bjc.6690597. PubMed: 10468296.
11. Metintas M, Ozdemir N, Uçgun I, Elbek O, Kolsuz M, et al. (1999) Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest 116: 391-398. doi:10.1378/chest.116.2.391. PubMed: 10453867.
12. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, et al. (2007) A phase I clinical trial of single-dose intrapleural IFN-β gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 13: 4456-4466. doi:10.1158/1078-0432.CCR-07-0403. PubMed: 17671130.
13. Sterman DH, Haas A, Moon E, Recio A, Schwed D, et al. (2011) A trial of intrapleural adenoviral-mediated Interferon-{alpha}2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 184: 1395-1399. doi:10.1164/rccm.201103-0554CR. PubMed: 21642245.
14. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, et al. (2003) Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523. doi:10.1038/nature01850. PubMed: 12872134.
15. Vannucchi S, Chiantore MV, Fiorucci G, Percario ZA, Leone S, et al. (2005) TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells. Oncogene 24: 2536-2546. doi:10.1038/sj.onc.1208403. PubMed: 15735750.
16. Ke Y, Reddel RR, Gerwin BI, Reddel HK, Somers AN, et al. (1989) Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol 134: 979-991. PubMed: 2541616.
17. Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, et al. (2010) Interferon-λ induces G1 phase arrest or apoptosis in esophageal carcinoma cells and produces anti-tumor effects in combination with anti-cancer agents. Eur J Cancer 46: 180-190. doi:10.1016/j.ejca.2009.10.002. PubMed: 19879751.
18. Deshpande A, Sicinski P, Hinds PW, (2005) Cyclins and cdks in development and cancer: a perspective. Oncogene 24: 2909-2915. doi:10.1038/sj.onc.1208618. PubMed: 15838524.
19. Satyanarayana A, Kaldis P, (2009) Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 28: 2925-2939. doi:10.1038/onc.2009.170. PubMed: 19561645.
20. Fujie H, Tanaka T, Tagawa M, Kaijun N, Watanabe M, et al. (2011) Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci 102: 1977-1990. doi:10.1111/j.1349-7006.2011.02079.x. PubMed: 21883692.
21. de Weerd NA, Samarajiwa SA, Hertzog PJ, (2007) Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282: 20053-20057. doi:10.1074/jbc.R700006200. PubMed: 17502368.
22. Sangfelt O, Erickson S, Castro J, Heiden T, Gustafsson A, et al. (1999) Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 18: 2798-2810. doi:10.1038/sj.onc.1202609. PubMed: 10362250.
23. Pokrovskaja K, Panaretakis T, Grandér D, (2005) Alternative signaling pathways regulating type I interferon-induced apoptosis. J Interferon Cytokine Res 25: 799-810. doi:10.1089/jir.2005.25.799. PubMed: 16375608.
24. Lu X, Errington J, Curtin NJ, Lunec J, Newell DR, (2001) The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res 7: 2114-2123. PubMed: 11448931.
25. Giovannetti E, Backus HH, Wouters D, Ferreira CG, van Houten VM, et al. (2007) Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 96: 769-775. doi:10.1038/sj.bjc.6603639. PubMed: 17339891.
26. Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, et al. (2013) Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and-independent signaling pathways. Mol Carcinog 52: 183-194. doi:10.1002/mc.21842. PubMed: 22086658.
27. Sandoval R, Xue J, Pilkinton M, Salvi D, Kiyokawa H, et al. (2004) Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines. J Biol Chem 279: 32275-32280. doi:10.1074/jbc.M313830200. PubMed: 15169789.
28. Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, et al. (2011) Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 37: 543-558. doi:10.1016/j.ctrv.2011.01.001. PubMed: 21288646.